新生血管性AMD相关黄斑下出血1年视力结局的预测因素
这项前瞻性观察队列研究纳入75只因nAMD或PCV导致黄斑区受累黄斑下出血的眼,均接受标准治疗。12个月时33.3%获良好视力结局,年轻、基线BCVA较好、黄斑中心凹下脉络膜较厚独立预测良好结局,出血面积较大预测不良结局。
要点
- 约三分之一黄斑下出血眼12个月BCVA达≤0.3 logMAR。
- 年轻、基线BCVA好、脉络膜厚预测良好视力结局。
- 出血面积较大独立预测12个月视力结局不良。
核心结论
- 年龄、基线BCVA和出血面积之外,脉络膜厚度是与黄斑下出血视力结局相关的生物标志物。
研究设计与样本
- 前瞻性观察性临床队列研究,纳入487只治疗初治眼中的75只符合黄斑区受累黄斑下出血标准的眼。
主要发现
- 12个月BCVA从1.04(0.67)logMAR改善至0.69(0.62)。
- 25眼(33.3%)达良好视力结局,22眼(29.3%)为不良视力结局。
关键数值与推荐
- 良好视力结局定义为12个月BCVA≤0.3 logMAR,不良为≥1.0 logMAR。
- 多变量分析:年轻(每十年OR=0.47,95%CI 0.26-0.86,P=.02)、基线BCVA较好(每0.1 logMAR OR=0.87,95%CI 0.79-0.97,P<.01)、黄斑中心凹下脉络膜较厚(每50µm OR=1.50,95%CI 1.07-2.10,P=.02)独立预测良好结局。
- 出血面积较大预测不良结局(每mm² OR=1.04,95%CI 1.01-1.07,P=.02)。
临床怎么用
- 评估黄斑下出血患者时可将年龄、基线BCVA、出血面积及黄斑中心凹下脉络膜厚度纳入预后判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify clinical and imaging predictors of 12-month visual outcome in patients with fovea-involving submacular hemorrhage (SMH) due to neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). DESIGN: Prospective observational clinical cohort study. SUBJECTS: Asian patients with nAMD or PCV presenting with fovea-involving SMH. METHODS: Between January 2016 and July 2024, eyes presenting with fovea-involving SMH ≥ 1 disc diameter with no evidence of blood organization were included. All patients received standard-of-care treatment. Clinical and multimodal imaging parameters were analyzed to identify predictors of visual outcome at 12 months. MAIN OUTCOME MEASURES: Good (≤0.3 logMAR) and poor (≥1.0 logMAR) visual outcomes at 12 months. RESULTS: Among 487 treatment-naïve eyes, 75 met inclusion criteria for fovea-involving SMH. Mean (SD) age was 71.40 (9.59) years, 74.4% were male, and 76.0% had PCV. Mean hemorrhage size was 19.45 (22.65) mm². All eyes received anti-VEGF therapy, 2.6% underwent additional pneumatic displacement, and 5.3% received photodynamic therapy. Best-corrected visual acuity (BCVA) improved from 1.04 (0.67) logMAR to 0.69 (0.62) at 12 months. 25 eyes (33.3%) achieved good visual outcome, while 22 eyes (29.3%) had poor visual outcome. On multivariable analysis, younger age (OR = 0.47 per decade, 95% CI: 0.26-0.86; P = .02), better baseline BCVA (OR = 0.87 per 0.1 logMAR, 95% CI: 0.79-0.97; P < .01), and thicker subfoveal choroid (OR = 1.50 per 50 µm, 95% CI: 1.07-2.10; P = .02) independently predicted good visual outcome. Conversely, larger hemorrhage size predicted poor visual outcome (OR = 1.04 per mm2, 95% CI: 1.01-1.07; P = .02). CONCLUSION: One-third of eyes with SMH achieved 0.3 logMAR (Snellen equivalent 20/40) or better vision. In addition to age, baseline BCVA, and hemorrhage size, we identified choroidal thickness as a biomarker associated with visual outcome.
引用
- Gilead N, Chong YJ, Cheng MFS, et al. Predictors of 1-Year Visual Outcome in Central-Involving Submacular Hemorrhage Secondary to Neovascular AMD. Am J Ophthalmol. 2026. PMID: 42177934. doi:10.1016/j.ajo.2026.05.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。